Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics Offers $0.324 Cash per Warrant to Repurchase Outstanding Warrants

Neutral Impact 2 of 5 financing Written later

Jasper Therapeutics, Inc. (Nasdaq: JSPR) commenced an offer to buy any and all of its outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant. The company said the offer aims to reduce the number of shares that could be issued on warrant exercise, which would lessen potential dilution and give shareholders more certainty about the capital structure.

Key points

  • Offer price is $0.324 in cash per warrant, without interest; each warrant exercisable for one share at $2.92.
  • As of October 6, 2026, 12,345,707 warrants were outstanding; if all are tendered, the company expects to pay about $4.0 million from cash on hand.
  • The offer expires at one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless extended or terminated, and is not conditioned on a minimum tender.
  • Warrants not tendered remain outstanding on their original terms and expire at 5:00 p.m. Eastern Time on March 18, 2030.

The filing

CompanyJasper Therapeutics, Inc. (JSPR)
Form8-K, current report
Filed with the SECOct 7, 2026, 8:05 AM ET
Accession number0001213900-26-107402

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.